©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Feb 6, 2016; 7(1): 107-111
Published online Feb 6, 2016. doi: 10.4292/wjgpt.v7.i1.107
Published online Feb 6, 2016. doi: 10.4292/wjgpt.v7.i1.107
Review of vedolizumab for the treatment of ulcerative colitis
Michelle SY Lau, Her Hsin Tsai, IBD Unit, Gastroenterology Department, Castle Hill Hospital, HEY NHS Trust, Cottingham HU16 5JQ, United Kingdom
Author contributions: Lau MSY carried out all the literature searches and prepared the manuscript; Tsai HH made several revisions and prepared the manuscript for publication.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Correspondence to: Her Hsin Tsai, MD, FRCP, IBD Unit, Gastroenterology Department, Castle Hill Hospital, HEY NHS Trust, Castle Road, Cottingham HU16 5JQ, United Kingdom. hhtsai@doctors.org.uk
Telephone: +44-1482-875875 Fax: +44-1482-622049
Received: June 10, 2015
Peer-review started: June 11, 2015
First decision: August 25, 2015
Revised: December 12, 2015
Accepted: December 29, 2015
Article in press: January 4, 2016
Published online: February 6, 2016
Processing time: 232 Days and 16.6 Hours
Peer-review started: June 11, 2015
First decision: August 25, 2015
Revised: December 12, 2015
Accepted: December 29, 2015
Article in press: January 4, 2016
Published online: February 6, 2016
Processing time: 232 Days and 16.6 Hours
Abstract
The review summarises the key data on the efficacy and the safety of vedolizumab in the management of ulcerative colitis.
Core tip: Vedolizumab appears to be effective in the management of moderate to severe ulcerative colitis with a good safety profile.